← Back to Search
Cholesterol Absorption Inhibitor
The Influence of Ezetimibe on Gallbladder Function
Indianapolis, IN
N/A
Waitlist Available
Led By Henry A. Pitt, MD
Research Sponsored by Indiana University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
All Individual Drugs Already Approved
Approved for 10 Other Conditions
Summary
Ezetimibe is a drug which inhibits the absorption of both dietary and biliary cholesterol in the small intestine. Ezetimibe has been approved for use in humans to lower serum cholesterol. The primary aim of this study is to determine if ezetimibe normalizes resting and residual volume in patients with chronic acalculous cholecystitis.
See full description
Eligible Conditions
- Chronic Cholecystitis
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 5 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
Treatment Details
Awards & Highlights
All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
Approved for 10 Other Conditions
This treatment demonstrated efficacy for 10 other conditions.
Trial Design
2Treatment groups
Experimental Treatment
Placebo Group
Group I: 1Experimental Treatment1 Intervention
ezetimibe
Group II: 2Placebo Group1 Intervention
placebo for 4-6 weeks
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Ezetimibe
FDA approved
Find a Location
Closest Location:Indiana University Hospital· Indianapolis, IN
Who is running the clinical trial?
Indiana UniversityLead Sponsor
1,055 Previous Clinical Trials
1,269,536 Total Patients Enrolled
Henry A. Pitt, MDPrincipal InvestigatorIndiana University